Biocryst Pharmaceuticals Inc (BCRX)

Sep 30, 2026

BioCryst Pharmaceuticals stock gets a USD 13.00 JPMorgan target - AD HOC NEWS

Sep 30, 2026

Sep 30, 2026

BioCryst Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by JP Morgan - Moomoo

Sep 30, 2026

Sep 30, 2026

BCRX Maintained by JP Morgan -- Price Target Raised to $13.00 - GuruFocus

Sep 30, 2026

Sep 29, 2026

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits

Sep 29, 2026

Sep 29, 2026

Claude AI Just Bought These 2 Pharma Stocks - Yahoo Finance

Sep 29, 2026

Sep 26, 2026

BCRX Should I Buy - Intellectia AI

Sep 26, 2026

Sep 25, 2026

(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Sep 25, 2026

Sep 24, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 24, 2026

Sep 23, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 23, 2026

Sep 23, 2026

Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks? - Yahoo Finance

Sep 23, 2026

Sep 22, 2026

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits

Sep 22, 2026

Sep 22, 2026

BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates - AD HOC NEWS

Sep 22, 2026

Sep 21, 2026

BioCryst Pharmaceuticals (BCRX) Edges Up 0.75% to $8.74 as Shares Approach Key ResistanceOption Breadth - siam.in

Sep 21, 2026

Sep 21, 2026

Biopharma Stock With Layers of Technical Support in Place - Yahoo Finance

Sep 21, 2026

Sep 18, 2026

BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Yahoo Finance

Sep 18, 2026

Sep 18, 2026

4 Biotech Stocks to Watch as Potential Takeover Targets - Yahoo Finance

Sep 18, 2026

Sep 17, 2026

BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - AlphaStreet

Sep 17, 2026

Sep 15, 2026

BCRX: External innovation and disciplined growth drive rare disease portfolio expansion and profitability - TradingView

Sep 15, 2026

Sep 15, 2026

BioCryst at Morgan Stanley conference: pivots to external growth - Investing.com

Sep 15, 2026

Sep 14, 2026

BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story - Yahoo Finance UK

Sep 14, 2026

Sep 12, 2026

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits

Sep 12, 2026

Sep 12, 2026

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits

Sep 12, 2026

Sep 11, 2026

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX) - Seeking Alpha

Sep 11, 2026

Sep 11, 2026

BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 11, 2026

Sep 10, 2026

RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures - Intellectia AI

Sep 10, 2026

Sep 10, 2026

BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus

Sep 10, 2026

Sep 10, 2026

BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’ - Yahoo Finance

Sep 10, 2026

Sep 09, 2026

BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus

Sep 09, 2026

Sep 09, 2026

BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews

Sep 09, 2026

Sep 08, 2026

BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI

Sep 08, 2026

Sep 08, 2026

CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - manilatimes.net

Sep 08, 2026

Sep 08, 2026

BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus

Sep 08, 2026

Sep 08, 2026

TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada

Sep 08, 2026

Sep 04, 2026

(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily

Sep 04, 2026

Sep 03, 2026

C5 inhibitors disclosed in Biocryst patents - BioWorld News

Sep 03, 2026

Sep 01, 2026

BioCryst to Present at Upcoming Investor Conference - marketscreener.com

Sep 01, 2026

Aug 31, 2026

BioCryst stock holds firm after a Q2 revenue beat - ad-hoc-news.de

Aug 31, 2026

Aug 31, 2026

Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Aug 31, 2026

Aug 28, 2026

BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset - Stocktwits

Aug 28, 2026

Aug 28, 2026

BioCryst Pharmaceuticals Inc. (BCRX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com

Aug 28, 2026

Aug 26, 2026

BCRXRevenue by Segment - Quiver Quantitative

Aug 26, 2026

Aug 26, 2026

Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm

Aug 26, 2026

Aug 25, 2026

BioCryst gets Japan approval for HAE drug in young children By Investing.com - Investing.com South Africa

Aug 25, 2026

Aug 25, 2026

BioCryst Pharmaceuticals Announces Japan Approval of ORLADEYO for Pediatric HAE Prophylaxis - Quiver Quantitative

Aug 25, 2026